197 related articles for article (PubMed ID: 17673618)
21. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.
Comin-Anduix B; Lee Y; Jalil J; Algazi A; de la Rocha P; Camacho LH; Bozon VA; Bulanhagui CA; Seja E; Villanueva A; Straatsma BR; Gualberto A; Economou JS; Glaspy JA; Gomez-Navarro J; Ribas A
J Transl Med; 2008 May; 6():22. PubMed ID: 18452610
[TBL] [Abstract][Full Text] [Related]
22. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.
Reuben JM; Lee BN; Li C; Gomez-Navarro J; Bozon VA; Parker CA; Hernandez IM; Gutierrez C; Lopez-Berestein G; Camacho LH
Cancer; 2006 Jun; 106(11):2437-44. PubMed ID: 16615096
[TBL] [Abstract][Full Text] [Related]
23. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
Ribas A; Comin-Anduix B; Economou JS; Donahue TR; de la Rocha P; Morris LF; Jalil J; Dissette VB; Shintaku IP; Glaspy JA; Gomez-Navarro J; Cochran AJ
Clin Cancer Res; 2009 Jan; 15(1):390-9. PubMed ID: 19118070
[TBL] [Abstract][Full Text] [Related]
24. Tumor regression and autoimmunity in cytotoxic T lymphocyte-associated antigen 4 blockade-treated patients.
Weber JS
Ann Surg Oncol; 2005 Dec; 12(12):957-9. PubMed ID: 16244797
[No Abstract] [Full Text] [Related]
25. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?
Robert C; Ghiringhelli F
Oncologist; 2009 Aug; 14(8):848-61. PubMed ID: 19648604
[TBL] [Abstract][Full Text] [Related]
26. Advances in the treatment of metastatic melanoma: new immunomodulatory agents.
Sznol M
Semin Oncol; 2012 Apr; 39(2):192-203. PubMed ID: 22484191
[TBL] [Abstract][Full Text] [Related]
27. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig.
Knoerzer DB; Karr RW; Schwartz BD; Mengle-Gaw LJ
J Clin Invest; 1995 Aug; 96(2):987-93. PubMed ID: 7543497
[TBL] [Abstract][Full Text] [Related]
28. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.
Eroglu Z; Kim DW; Wang X; Camacho LH; Chmielowski B; Seja E; Villanueva A; Ruchalski K; Glaspy JA; Kim KB; Hwu WJ; Ribas A
Eur J Cancer; 2015 Nov; 51(17):2689-97. PubMed ID: 26364516
[TBL] [Abstract][Full Text] [Related]
29. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers.
Tarhini AA; Kirkwood JM
Expert Opin Biol Ther; 2008 Oct; 8(10):1583-93. PubMed ID: 18774925
[TBL] [Abstract][Full Text] [Related]
30. Ipilimumab: showing survival benefit in metastatic melanoma.
Minchom A; Young K; Larkin J
Future Oncol; 2011 Nov; 7(11):1255-64. PubMed ID: 22044200
[TBL] [Abstract][Full Text] [Related]
31. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.
Straatsma BR; Nusinowitz S; Young TA; Gordon LK; Chun MW; Rosen C; Seja E; Economou JS; Glaspy JA; Bozon V; Gomez-Navarro J; Ribas A
Am J Ophthalmol; 2007 Jun; 143(6):958-969. PubMed ID: 17434437
[TBL] [Abstract][Full Text] [Related]
32. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
Hodi FS; Mihm MC; Soiffer RJ; Haluska FG; Butler M; Seiden MV; Davis T; Henry-Spires R; MacRae S; Willman A; Padera R; Jaklitsch MT; Shankar S; Chen TC; Korman A; Allison JP; Dranoff G
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4712-7. PubMed ID: 12682289
[TBL] [Abstract][Full Text] [Related]
33. Update on anti-CTLA-4 antibodies in clinical trials.
Langer LF; Clay TM; Morse MA
Expert Opin Biol Ther; 2007 Aug; 7(8):1245-56. PubMed ID: 17696822
[TBL] [Abstract][Full Text] [Related]
34. Immune modulation in melanoma and advanced cancer therapy: anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibodies.
Esper P
Clin J Oncol Nurs; 2009 Oct; 13(5):547-54. PubMed ID: 19793711
[TBL] [Abstract][Full Text] [Related]
35. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4.
Dias JD; Hemminki O; Diaconu I; Hirvinen M; Bonetti A; Guse K; Escutenaire S; Kanerva A; Pesonen S; Löskog A; Cerullo V; Hemminki A
Gene Ther; 2012 Oct; 19(10):988-98. PubMed ID: 22071969
[TBL] [Abstract][Full Text] [Related]
36. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.
Ribas A; Chesney JA; Gordon MS; Abernethy AP; Logan TF; Lawson DH; Chmielowksi B; Glaspy JA; Lewis K; Huang B; Wang E; Hsyu PH; Gomez-Navarro J; Gerhardt D; Marshall MA; Gonzalez R
J Transl Med; 2012 Nov; 10():236. PubMed ID: 23171508
[TBL] [Abstract][Full Text] [Related]
37. Combined CTLA4Ig and anti-CD4/DC8 monoclonal antibody treatment prolongs survival of rat-to-mouse heterotopic cardiac xenografts.
Rehman A; Tu Y; Flye MW
Transplant Proc; 1996 Apr; 28(2):660-1. PubMed ID: 8623331
[No Abstract] [Full Text] [Related]
38. Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population.
Anderson DE; Bieganowska KD; Bar-Or A; Oliveira EM; Carreno B; Collins M; Hafler DA
Nat Med; 2000 Feb; 6(2):211-4. PubMed ID: 10655112
[TBL] [Abstract][Full Text] [Related]
39. A phase 2 study of tremelimumab in patients with advanced uveal melanoma.
Joshua AM; Monzon JG; Mihalcioiu C; Hogg D; Smylie M; Cheng T
Melanoma Res; 2015 Aug; 25(4):342-7. PubMed ID: 26050146
[TBL] [Abstract][Full Text] [Related]
40. Ipilimumab: a promising immunotherapy for melanoma.
Thumar JR; Kluger HM
Oncology (Williston Park); 2010 Dec; 24(14):1280-8. PubMed ID: 21294471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
